Schaffner, William

Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 states, march 1-30, 2020

Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report

COVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

Cited by 2,335

Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

Kim, L., Garg, S., O’Halloran, A., Whitaker, M., Pham, H., Anderson, E. J., Armistead, I., Bennett, N. M., Billing, L., Como-Sabetti, K., et al. (2021) · Clinical Infectious Diseases

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 649

Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis

Hsu, H. E., Shutt, K. A., Moore, M. R., Beall, B. W., Bennett, N. M., Craig, A. S., Farley, M. M., Jorgensen, J. H., Lexau, C. A., Petit, S., et al. (2009) · New England Journal of Medicine

Pneumonia and Respiratory InfectionsBacterial Infections and Vaccines

Cited by 497

Asthma as a risk factor for invasive pneumococcal disease

Talbot, T. R., Hartert, T. V., Mitchel, E., Halasa, N. B., Arbogast, P. G., Poehling, K. A., Schaffner, W., Craig, A. S., & Griffin, M. R. (2005) · New England Journal of Medicine

Pneumonia and Respiratory InfectionsAsthma and respiratory diseases

Cited by 395

Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

Cohn, A. C., MacNeil, J. R., Harrison, L. H., Hatcher, C., Theodore, J., Schmidt, M., Pondo, T., Arnold, K. E., Baumbach, J., Bennett, N., et al. (2010) · Clinical Infectious Diseases

Bacterial Infections and VaccinesMicrobial infections and disease research

Cited by 345

Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021

Delahoy, M. J., Ujamaa, D., Whitaker, M., O'Halloran, A., Anglin, O., Burns, E., Cummings, C., Holstein, R., Kambhampati, A. K., Milucky, J., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

COVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

Cited by 273

Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance

Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 231

Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016

Toda, M., Williams, S. R., Berkow, E. L., Farley, M. M., Harrison, L. H., Bonner, L., Marceaux, K. M., Hollick, R., Zhang, A. Y., Schaffner, W., et al. (2019) · MMWR Surveillance Summaries

Antifungal resistance and susceptibilityYeasts and Rust Fungi Studies

Cited by 198

Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based Candidemia Surveillance Program, 2008–2014

Vallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., Derado, G., Pham, C. D., Lockhart, S. R., & Smith, R. M. (2015) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 187

Burden of Candidemia in the United States, 2017

Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 163

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021

Moline, H. L., Whitaker, M., Deng, L., Rhodes, J. C., Milucky, J., Pham, H., Patel, K., Anglin, O., Reingold, A., Chai, S. J., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 161

The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic

Seagle, E. E., Jackson, B. R., Lockhart, S. R., Georgacopoulos, O., Nunnally, N. S., Roland, J., Barter, D. M., Johnston, H. L., Czaja, C. A., Kayalioglu, H., et al. (2022) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityCOVID-19 Clinical Research Studies

Cited by 141

Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs — Six Sites, 2005–2016

Jackson, K. A., Bohm, M. K., Brooks, J. T., Asher, A., Nadle, J., Bamberg, W. M., Petit, S., Ray, S. M., Harrison, L. H., Lynfield, R., et al. (2018) · MMWR. Morbidity and Mortality Weekly Report

Antimicrobial Resistance in StaphylococcusHIV, Drug Use, Sexual Risk

Cited by 139

Socioeconomic Factors Explain Racial Disparities in Invasive Community-Associated Methicillin-Resistant Staphylococcus aureus Disease Rates

See, I., Wesson, P., Gualandi, N., Dumyati, G., Harrison, L. H., Lesher, L., Nadle, J., Petit, S., Reisenauer, C., Schaffner, W., et al. (2017) · Clinical Infectious Diseases

Antimicrobial Resistance in StaphylococcusHealth disparities and outcomes

Cited by 105

Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci

Kainer, M. A., Devasia, R. A., Jones, T. F., Simmons, B. P., Melton, K., Chow, S., Broyles, J., Moore, K. L., Craig, A. S., & Schaffner, W. (2007) · Emerging Infectious Diseases

Antibiotic Resistance in BacteriaInfection Control in Healthcare

Cited by 96

Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations, 2009–2015

Benedict, K., Roy, M., Kabbani, S., Anderson, E. J., Farley, M. M., Harb, S., Harrison, L. H., Bonner, L., Wadu, V. L., Marceaux, K., et al. (2018) · Journal of the Pediatric Infectious Diseases Society

Antifungal resistance and susceptibilityNeonatal and Maternal Infections

Cited by 81

Family Outbreaks of Invasive Community-Associated Methicillin-Resistant Staphylococcus aureus Infection

Jones, T. F., Creech, C. B., Erwin, P., Baird, S. G., Woron, A. M., & Schaffner, W. (2006) · Clinical Infectious Diseases

Antimicrobial Resistance in StaphylococcusInfection Control in Healthcare

Cited by 67

The Changing Epidemiology of Candidemia in the United States: Injection Drug Use as an Increasingly Common Risk Factor—Active Surveillance in Selected Sites, United States, 2014–2017

Zhang, A. Y., Shrum, S., Williams, S., Petnic, S., Nadle, J., Johnston, H., Barter, D., Vonbank, B., Bonner, L., Hollick, R., et al. (2020) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 54

Population-Based Active Surveillance for Culture-Confirmed Candidemia — 10 Sites, United States, 2017–2021

Jenkins, E. N., Gold, J. A. W., Benedict, K., Lockhart, S. R., Berkow, E. L., Dixon, T., Shack, S. L., Witt, L. S., Harrison, L. H., Seopaul, S., et al. (2025) · MMWR. Surveillance Summaries

Antifungal resistance and susceptibilityYeasts and Rust Fungi Studies

Cited by 43

Risk Factors for Invasive Methicillin-Resistant Staphylococcus aureus Infection After Recent Discharge From an Acute-Care Hospitalization, 2011–2013

Epstein, L., Mu, Y., Belflower, R., Scott, J., Ray, S., Dumyati, G., Felsen, C., Petit, S., Yousey-Hindes, K., Nadle, J., et al. (2016) · Clinical Infectious Diseases

Antimicrobial Resistance in StaphylococcusInfection Control in Healthcare

Cited by 41

Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018.

Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 20

Injection Drug Use-Associated Candidemia: Incidence, Clinical Features, and Outcomes, East Tennessee, 2014–2018

Rossow, J. A., Gharpure, R., Brennan, J., Relan, P., Williams, S. R., Vallabhaneni, S., Jackson, B. R., Graber, C. R., Hillis, S. R., Schaffner, W., et al. (2020) · The Journal of Infectious Diseases

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 17

1722. The changing epidemiology of candidemia in the United States: injection drug use as an emerging risk factor for candidemia

Zhang, A. Y., Shrum, S., Williams, S., Vonbank, B., Hillis, S., Barter, D., Petnic, S., Harrison, L. H., Dumyati, G., Phipps, E. C., et al. (2018) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 2